NO311867B1 - Fremgangsmåte for kondisjonering av vannopplöselige stoffer - Google Patents

Fremgangsmåte for kondisjonering av vannopplöselige stoffer Download PDF

Info

Publication number
NO311867B1
NO311867B1 NO19933575A NO933575A NO311867B1 NO 311867 B1 NO311867 B1 NO 311867B1 NO 19933575 A NO19933575 A NO 19933575A NO 933575 A NO933575 A NO 933575A NO 311867 B1 NO311867 B1 NO 311867B1
Authority
NO
Norway
Prior art keywords
substances
solvent
inert gas
micronized
conditioning
Prior art date
Application number
NO19933575A
Other languages
English (en)
Norwegian (no)
Other versions
NO933575D0 (no
NO933575L (no
Inventor
Jan Trofast
Eva Trofast
Katarina Bystroem
Edib Jakupovic
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20382434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO311867(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO933575D0 publication Critical patent/NO933575D0/no
Publication of NO933575L publication Critical patent/NO933575L/no
Publication of NO311867B1 publication Critical patent/NO311867B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Hydrogenated Pyridines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Cosmetics (AREA)
  • Cephalosporin Compounds (AREA)
  • Treating Waste Gases (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO19933575A 1991-04-11 1993-10-06 Fremgangsmåte for kondisjonering av vannopplöselige stoffer NO311867B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101090A SE9101090D0 (sv) 1991-04-11 1991-04-11 Process for conditioning of water-soluble substances
PCT/SE1992/000186 WO1992018110A1 (en) 1991-04-11 1992-03-24 Process for conditioning of water-soluble substances

Publications (3)

Publication Number Publication Date
NO933575D0 NO933575D0 (no) 1993-10-06
NO933575L NO933575L (no) 1993-10-06
NO311867B1 true NO311867B1 (no) 2002-02-11

Family

ID=20382434

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19933575A NO311867B1 (no) 1991-04-11 1993-10-06 Fremgangsmåte for kondisjonering av vannopplöselige stoffer

Country Status (28)

Country Link
US (1) US5562923A (enExample)
EP (3) EP0680752B1 (enExample)
JP (2) JP3400999B2 (enExample)
KR (1) KR100216384B1 (enExample)
AT (2) ATE208613T1 (enExample)
AU (1) AU662519B2 (enExample)
BG (1) BG61474B1 (enExample)
CA (1) CA2106975C (enExample)
CZ (1) CZ286936B6 (enExample)
DE (2) DE69232207T2 (enExample)
DK (2) DK0680752T3 (enExample)
EE (1) EE02970B1 (enExample)
ES (2) ES2168322T3 (enExample)
FI (1) FI105388B (enExample)
GR (1) GR3020602T3 (enExample)
HK (1) HK52497A (enExample)
HU (1) HU211116B (enExample)
IE (1) IE921144A1 (enExample)
IS (1) IS3834A (enExample)
NO (1) NO311867B1 (enExample)
PL (1) PL168232B1 (enExample)
PT (1) PT680752E (enExample)
RO (1) RO115779B1 (enExample)
RU (1) RU2112507C1 (enExample)
SE (1) SE9101090D0 (enExample)
SG (1) SG43180A1 (enExample)
SK (1) SK280310B6 (enExample)
WO (1) WO1992018110A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
CN1090935C (zh) * 1995-02-28 2002-09-18 阿温蒂斯药物公司 哌啶子基烷醇化合物的药物组合物
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CN100518718C (zh) * 1997-03-20 2009-07-29 先灵公司 粉末附聚物的制备方法
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
BR9812693A (pt) * 1997-09-29 2000-08-22 Inhale Therapeutic Syst Uso de um agente bioativo, processo para formar uma microestrutura perfurada, microestrutura perfurada, processo para aumentar a dispersibilidade de um pó, pó de microestrutura perfurada, pó tendo dispersibilidade aumentada, sistema de inalação para a administração pulmonar de um agente bioativo a um paciente, e, processo para a liberação pulmonar de um ou mais agentes bioativos
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
FI105074B (fi) * 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US6623760B1 (en) 1999-01-28 2003-09-23 Schering Corporation Method of preparing particles for agglomeration
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0228826D0 (en) * 2002-12-11 2003-01-15 Okpala Joseph Hair technology in creating particles with improved delivery capabilities
ES2233227T1 (es) * 2003-03-26 2005-06-16 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de ingredientes farmaceuticos activos con un area superficial especifica.
CN101816662B (zh) * 2003-06-13 2015-01-28 约翰·克劳斯·萨沃伊尔 由雌二醇和胆固醇组成的稳定形状颗粒的制备方法
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
AU2004281270B2 (en) * 2003-10-17 2010-05-06 E.I. Dupont De Nemours And Company Adhesion of foil to thermoplastic polymers
AU2005210236B2 (en) * 2004-02-03 2010-09-09 Chemagis Ltd. Stable amorphous forms of montelukast sodium
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
DE102004048390A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
BRPI0821186A2 (pt) * 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
RU2376079C1 (ru) * 2008-06-11 2009-12-20 Государственное образовательное учреждение высшего профессионального образования "Московский государственный университет инженерной экологии" Способ получения порошков микронизированных частиц
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
RU2013153466A (ru) 2011-06-29 2015-08-10 Астразенека Аб Кристаллическая форма производных индазолиламида для лечения опосредованных глюкокортикоидными рецепторами расстройств
US20140275517A1 (en) * 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978192A (en) * 1971-09-23 1976-08-31 Sussman Martin V Method of drawing fibers using a microterraced drawing surface
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
JPH08186B2 (ja) * 1985-06-21 1996-01-10 ゲルゲリイ、ゲルハルト プロセス材料から反応生成物を製造する方法及びその装置
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
PH30058A (en) * 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Also Published As

Publication number Publication date
DE69210601D1 (de) 1996-06-13
EP0580648A1 (en) 1994-02-02
CA2106975C (en) 2002-03-19
NO933575D0 (no) 1993-10-06
NO933575L (no) 1993-10-06
JPH06506454A (ja) 1994-07-21
HU211116B (en) 1995-10-30
HU9302870D0 (en) 1993-12-28
GR3020602T3 (en) 1996-10-31
ATE208613T1 (de) 2001-11-15
DK0580648T3 (da) 1996-09-16
SK108893A3 (en) 1994-03-09
PT680752E (pt) 2002-05-31
ES2086733T3 (es) 1996-07-01
CA2106975A1 (en) 1992-10-12
SE9101090D0 (sv) 1991-04-11
HK52497A (en) 1997-05-02
IE921144A1 (en) 1992-10-21
SK280310B6 (sk) 1999-11-08
BG61474B1 (en) 1997-09-30
HUT65095A (en) 1994-04-28
FI934429A0 (fi) 1993-10-08
FI934429L (fi) 1993-10-08
SG43180A1 (en) 1997-10-17
JP3400999B2 (ja) 2003-04-28
RO115779B1 (ro) 2000-06-30
FI105388B (fi) 2000-08-15
RU2112507C1 (ru) 1998-06-10
EP0680752A2 (en) 1995-11-08
EP0680752B1 (en) 2001-11-14
IS3834A (is) 1992-10-12
KR100216384B1 (ko) 1999-08-16
US5562923A (en) 1996-10-08
ES2168322T3 (es) 2002-06-16
CZ286936B6 (cs) 2000-08-16
EP0580648B1 (en) 1996-05-08
DK0680752T3 (da) 2002-02-25
DE69210601T2 (de) 1996-10-02
EP0680752A3 (enExample) 1995-11-22
BG98147A (bg) 1994-12-02
JP2003155228A (ja) 2003-05-27
EP0508969A1 (en) 1992-10-14
AU1534792A (en) 1992-11-17
WO1992018110A1 (en) 1992-10-29
EE02970B1 (et) 1997-04-15
DE69232207T2 (de) 2002-08-01
PL168232B1 (pl) 1996-01-31
AU662519B2 (en) 1995-09-07
CZ211693A3 (en) 1994-04-13
ATE137671T1 (de) 1996-05-15
DE69232207D1 (de) 2001-12-20

Similar Documents

Publication Publication Date Title
NO311867B1 (no) Fremgangsmåte for kondisjonering av vannopplöselige stoffer
RU93058260A (ru) Способ получения водорастворимых микронизированных веществ
CA2022104C (en) Supercritical fluid and near critical gas extraction of organic solvents from formed articles
RU93004547A (ru) Фармацевтический состав на основе tanacetum partheniom, способ его получения и лекарственное средство на его основе
JPH09508695A (ja) 溶液から材料を乾燥する方法
EP0394050A3 (en) A method of preparing a freeze-dried formulation containing a drug
KR100944059B1 (ko) 퓨란 리피드가 풍부한 아보카도 잎 식물 추출물을 얻는 방법
Smolarz Comparative study on the free flavonoid aglycones in herbs of different species of Polygonum L
JP3345660B2 (ja) クラタエグス種の調製物、医薬組成物ならびに心拍停止および再潅流により引き起こされる心臓血管損傷による突然死を防止するためのその使用
PL197514B1 (pl) Sposób wytwarzania wyciągu z Tanacetum parthenium, kompozycja farmaceutyczna i kompozycja kosmetyczna zawierające ten wyciąg
IE36411B1 (en) A method for obtaining tobacco aroma substances
RU2006126051A (ru) Способы получения партии активного фармацевтического ингредиента, контейнер, содержащий криогранулы аллергенного продукта, и криогранула аллергенного продукта
ES2061713T3 (es) Nuevas formas galenicas de corticoides para administracion por via per- y sublingual y su procedimiento de preparacion.
ATE86477T1 (de) Galenische form eines trockenextraktes von pflanzen.
JP3540326B2 (ja) 高濃度バレレン酸含有バレリアナ・オフィシナリスからの抽出物を製造する方法
IT1188633B (it) Procedimento per ottenere un estratto standardizzato di frutti di palma dotato di attivita' farmaceutica
Rice et al. Freeze-drying for electron microscopy
CN1215057C (zh) 用冷冻干燥方式从中药提取液中分离回收二甲基亚砜的方法
RU94004928A (ru) Способ получения липидов из лечебных грязей
Ruml et al. A model for the erosion of steam turbine blade materials
KR920000329A (ko) 에키나시아 추출물, 그 제조방법 및 그들을 함유한 배합물
Thomas et al. Critical point drying of liverwort spores for scanning electron microscopy
Zaitsev et al. Thermodynamic Investigation of the DyPd Phase in the Homogeneity Region
BAKHAREV et al. The effect of the neuropeptides vasopressin and fragments of corticotrophin on the cardiovascular and respiratory system of humans at rest and during physical loading
Menichini et al. P301 pharmacological activity of centaurea deusta ten

Legal Events

Date Code Title Description
MK1K Patent expired